
According to a report by The Guardian on January 2nd, the UK has approved the sale of a smoking cessation drug called Cytisine, which could play a significant role in helping people quit smoking.
Even though many smokers have turned to nicotine alternative products that are safer than cigarettes, doctors have discovered a drug called cytisine (a natural ingredient found in the seeds of the golden chain tree) that can help smokers quit their addiction, with a success rate of more than double. This drug has been in use in Central and Eastern Europe for decades but is not available in most countries, including the United States. Recently, it gained approval from regulatory authorities in the United Kingdom and is expected to hit the market at the end of this month.
Argentinian researchers conducted a thorough analysis of 12 randomized controlled trials comparing the success rates of smokers using Cytisine, a placebo, another smoking cessation drug called Champix, or nicotine replacement therapies such as patches or nicotine pouches.
Researchers have discovered that Cytisine, a plant alkaloid, is more than twice as effective as a placebo. Several studies under review indicate that this medication has similarities to Varenicline and might be more effective than nicotine replacement therapy.
According to Argentine toxicologist Omar, "Smoking is considered a major preventable cause of death worldwide. Nicotine may become one of the important solutions to address this issue."
The alkaloid vincamine will be available on the market in the UK as a prescription drug by the end of January. However, the cost of a 25-day treatment with 100 pills is £115, which may hinder certain regions from including this medication as part of their healthcare services for the public.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com